Welcome to our dedicated page for Esperion Therape SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Esperion Therapeutics, Inc. (ESPR) SEC filings page provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Esperion is a commercial-stage biopharmaceutical company listed on the Nasdaq Stock Market LLC under the symbol ESPR, and its filings offer detailed insight into its cardiometabolic and rare/orphan disease business, including oral non-statin LDL-C therapies such as NEXLETOL and NEXLIZET.
Key filing types for Esperion include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, risk factors, financial statements, and discussion of operations. Current reports on Form 8-K and 8-K/A, several of which are referenced in the provided data, disclose material events such as financial results, underwritten public offerings of common stock, executive appointments, board changes, and other significant corporate developments.
Investors can also review notifications of late filing on Form 12b-25, which explain delays in periodic reports and provide management’s narrative regarding the status of financial closing procedures. For Esperion, these documents have included explanations related to quarterly financial close and corrections to previously furnished earnings releases.
On Stock Titan, Esperion’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the content of lengthy documents, highlight key sections, and surface items such as revenue drivers, commercialization plans for NEXLETOL and NEXLIZET, capital-raising transactions, and changes in executive leadership. Users can also identify trading symbol information, exchange listing details, and other disclosures related to Esperion’s common stock directly from these filings.
Esperion Therapeutics General Counsel Benjamin Looker reported a small sale of company stock. On 01/20/2026, he sold 1,689 shares of Esperion Therapeutics common stock at a price of $2.882 per share. According to the filing, the shares were sold to satisfy tax obligations arising from vested restricted stock units, meaning the transaction was linked to covering taxes rather than a discretionary open-market sale. Following this transaction, he beneficially owned 384,216 shares directly.
Esperion Therapeutics insider plans a small Rule 144 stock sale. A person named Benjamin Looker filed notice to sell 1,689 shares of common stock of Esperion through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $4,867.02 and 239,063,437 common shares outstanding. The shares to be sold were acquired on 01/15/2026 through restricted stock vesting from the issuer as compensation. Over the prior three months, the same seller disposed of 6,517 common shares on 12/17/2025 for gross proceeds of $23,897.19. By signing the notice, the seller represents that he is not aware of any undisclosed material adverse information about Esperion’s operations.
Esperion Therapeutics, Inc. reported preliminary 2025 results and shared expense guidance for the fiscal year ending December 31, 2026. Management currently expects 2026 research and development expenses to range from $40 million to $50 million, selling, general and administrative expenses to range from $170 million to $195 million, and total operating expenses to range from $210 million to $245 million. The figures reflect management’s current expectations and were released in connection with the company’s presentation at the Annual J.P. Morgan Healthcare Conference.
Esperion Therapeutics, Inc. reported an insider stock transaction by its President and CEO, who is also a director. On 12/17/2025, the insider sold 48,244 shares of common stock at $3.673 per share. After this transaction, the insider beneficially owned 1,470,587 shares of Esperion common stock.
The company states that these shares were sold to satisfy tax obligations arising from vested restricted stock units, meaning the sale was tied to covering taxes rather than a discretionary reduction of ownership.
Esperion Therapeutics Chief Financial Officer Sheldon L. Koenig reported a routine stock transaction involving company shares. On 12/17/2025, he sold 7,337 shares of Esperion Therapeutics common stock at a price of $3.667 per share. According to the filing, these shares were sold to cover tax obligations arising from the vesting of restricted stock units. After this sale, Koenig beneficially owned 467,525 shares of Esperion common stock, held directly.
Esperion Therapeutics, Inc. reported an insider stock transaction by its General Counsel. On 12/17/2025, the officer sold 6,517 shares of common stock at a price of $3.667 per share. According to the explanation, these shares were sold to satisfy tax obligations arising from vested restricted stock units, meaning the sale was related to tax withholding rather than a discretionary liquidation of holdings. Following this transaction, the reporting person directly owned 385,905 shares of Esperion common stock.
Esperion Therapeutics, Inc. filed an initial ownership report for a senior executive showing no equity holdings. The filing is a Form 3 for the company’s Chief Commercial Officer, who is classified as an officer of Esperion Therapeutics, Inc. (ticker ESPR). The event date for this ownership status is listed as 11/17/2025. According to the remarks, no securities of Esperion, either direct or derivative, are beneficially owned by this reporting person as of that date.
Esperion Therapeutics (ESPR) reported Q3 2025 results showing stronger top-line momentum but ongoing losses. Total revenue reached $87.3 million, up from $51.6 million a year ago, driven by product sales of $40.7 million (vs. $31.1 million) and collaboration revenue of $46.7 million (vs. $20.5 million). Operating loss narrowed to $10.0 million, but higher interest expense brought net loss to $31.3 million (vs. $29.5 million). Year‑to‑date, revenue was $234.7 million with a net loss of $84.5 million.
Cash and cash equivalents were $92.4 million as of September 30, 2025, with operating cash outflow of $58.3 million year‑to‑date. The balance sheet reflects a royalty sale liability of $294.2 million (interest expense $14.6 million in Q3) and long‑term debt of $151.7 million under a December 2024 credit agreement. Accounts receivable grew to $119.0 million and inventories to $108.5 million, supporting higher sales. The company settled several generic challenges in 2025 and continues defending remaining ANDA cases; certain asserted patents extend into 2040. Shares outstanding were 239,063,437 as of October 31, 2025.
Esperion Therapeutics filed a Form 8-K stating it furnished a press release announcing financial results for the three and nine months ended September 30, 2025.
The information under Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference under the Securities Act except as specifically referenced.
Esperion Therapeutics appointed John B. Harlow, Jr. as Chief Commercial Officer, effective November 17, 2025. The hire adds a veteran commercial leader with prior CCO roles at Melinta Therapeutics and Baudax Bio.
Under his agreement, Harlow will receive a $535,000 base salary, a target bonus equal to 45% of salary, and a $35,000 sign-on bonus. Equity awards include options for 380,000 shares at the grant-date closing price and 424,536 RSUs, each vesting over four years, subject to continued service. Severance provides one year of salary (and, upon a sale event, salary plus target bonus) and COBRA-related cash payments, subject to customary release conditions.